- Conditions
- Neurofibromatosis 2, Meningioma
- Interventions
- AZD2014
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 185
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bilateral Cochlear Aplasia, Bilateral Cochlear Nerve Deficiency, Bilateral Cochlear Ossification Secondary to Meningitis
- Interventions
- Auditory brainstem implant
- Device
- Lead sponsor
- House Research Institute
- Other
- Eligibility
- 2 Years to 5 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Selumetinib granule formulation, Selumetinib capsule formulation
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Year to 6 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 4
- States / cities
- Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Not listed
- Lead sponsor
- Shriners Hospitals for Children
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Neoplasms, Nervous System Disease, Vestibular Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- SkylineDx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,820 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more
- Conditions
- Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor
- Interventions
- Computed Tomography, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Quality-of-Life Assessment, Single Photon Emission Computed Tomography, Magnetic Resonance Imaging, Ultrasound Imaging, Biospecimen Collection, Biopsy, Questionnaire Administration
- Procedure · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Solid Tumors, Lung Cancer
- Interventions
- BKM120, Everolimus
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- NF1, Neurofibromatosis, Cutaneous Neurofibroma, Neurofibroma, Von Recklinghausen Disease, Neurofibromas
- Interventions
- Imlygic
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Lovastatin ™, placebo
- Drug · Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 8 Years to 15 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Neurofibromatosis, NF1, Neurofibromas
- Interventions
- Tasigna
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Neurofibromatosis, MPNST
- Interventions
- MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 10 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neurofibromatosis 2
- Interventions
- Stress Management Group 1, Stress Management Group 2
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glioma, Neurofibromatosis Type 1
- Interventions
- Not listed
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
- Interventions
- Brigatinib, Neratinib, Retifanlimab, Bevacizumab
- Drug
- Lead sponsor
- Scott R. Plotkin, MD, PhD
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Miami, Florida • Indianopolis, Indiana + 3 more
- Conditions
- NF type1 With Inoperable Plexiform Neurofibromas
- Interventions
- Selumetinib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 2 Years to 130 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Cancer, HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 7 Years to 21 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glioma
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Frameshift Array blood sample test
- Genetic
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 1 Day to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Dallas, Texas
- Conditions
- Bilateral Hearing Loss for Causes Other Than Tumors
- Interventions
- Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
- Device
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cutaneous Neurofibroma
- Interventions
- Kybella, 1064nm laser, 755nm Alexandrite Laser
- Drug · Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neurofibromatosis Type 1, Tumors of the Central Nervous System
- Interventions
- Collection of Stem Cells
- Diagnostic Test
- Lead sponsor
- Roger Packer
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Neurofibromatosis 1
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 7 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neurofibromatosis 1, Plexiform Neurofibroma
- Interventions
- Selumetinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Year to 8 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 11 more